PRAMEF9 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of PRAMEF9, a member of the Preferentially Expressed Antigen in Melanoma Family (PRAME). PRAMEF9, like other PRAME family proteins, is believed to play a role in regulating gene expression by interacting with transcriptional machinery and influencing various cellular processes such as cell growth, proliferation, differentiation, and apoptosis. Although the precise function of PRAMEF9 has not been fully characterized, it is likely involved in modulating transcriptional programs that control gene expression in response to environmental signals, developmental cues, and stress conditions. PRAME family proteins often interact with transcriptional repressors or co-activators, and by inhibiting PRAMEF9, researchers can explore its role in gene regulation and cellular homeostasis.
In research, PRAMEF9 inhibitors serve as powerful tools to investigate the molecular mechanisms underlying transcriptional regulation and how PRAMEF9 impacts cellular function. By blocking PRAMEF9 activity, scientists can study how its inhibition alters gene expression patterns, providing insights into how PRAMEF9 contributes to the control of key processes such as cell cycle regulation and cellular differentiation. This inhibition also allows for the exploration of the downstream effects on critical signaling pathways and protein networks that are influenced by PRAMEF9-mediated transcriptional activity. Additionally, PRAMEF9 inhibitors offer a unique opportunity to examine how this protein interacts with other PRAME family members or transcriptional complexes, shedding light on the broader regulatory networks that influence gene expression and cellular function. Through these studies, the use of PRAMEF9 inhibitors enhances our understanding of transcriptional control mechanisms, PRAME family functions, and the complex biological processes that regulate cellular growth and adaptation to changing environmental or physiological conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
May demethylate promoter regions upstream of PRAMEF9 leading to its transcriptional silencing through changes in chromatin accessibility. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Could target DNA methyltransferases, potentially resulting in decreased methylation and subsequent silencing of PRAMEF9 gene transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Might hyperacetylate histones around the PRAMEF9 locus, leading to chromatin remodeling and a subsequent decrease in PRAMEF9 mRNA synthesis. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Could lead to the accumulation of acetylated histones, potentially repressing transcriptional initiation at the PRAMEF9 gene. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
May directly inhibit DNA methyltransferase activity, resulting in reduced PRAMEF9 expression due to hypomethylation of its promoter region. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
Might selectively inhibit class I histone deacetylases, leading to a downregulation of PRAMEF9 through altered gene expression patterns. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Could non-selectively inhibit histone deacetylases, leading to widespread changes in gene expression including a potential reduction in PRAMEF9 levels. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
May bind to specific DNA sequences within the PRAMEF9 promoter and directly inhibit its transcriptional activity. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Could bind tightly to DNA sequences, particularly at transcription initiation complexes, and inhibit PRAMEF9 mRNA elongation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Might disrupt the binding of bromodomain-containing proteins to acetylated histones, leading to transcriptional repression of PRAMEF9. | ||||||